Background Cetuximab plus platinum‐based therapy (PBT) followed by cetuximab
maintenance until progression (EXTREME) is a guideline‐recommended first‐line treatment …

Background: The EXTREME regimen (cetuximab+ PBT≤ 6 cycles followed by cetuximab-
alone maintenance until progressive disease [PD]) was the first treatment in 30 years to …

Background: The randomized, phase 3 EXTREME study established cetuximab+ platinum+
5-flurouracil (5-FU) followed by cetuximab maintenance until progressive disease (PD) as …

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
(SCCHN) have a poor prognosis, particularly those whose disease has progressed on …

Aim: Cetuximab combined with platinum is the standard first-line therapy in patients (pts)
with R/M SCCHN. DIRECT is the first multicenter prospective observational study evaluating …

BACKGROUND. The epidermal growth factor receptor (EGFR) inhibitor cetuximab is active
in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The …

5505 Background: Patients with R&M SCCHN have a poor prognosis. Patients failing first-
line therapy have few therapeutic options. Cetuximab (Erbitux) is an IgG1 monoclonal …

Purpose To evaluate the efficacy and safety of the epidermal growth factor receptor–directed
monoclonal antibody cetuximab administered as a single agent in patients with recurrent …

5567 Background: Cetuximab in combination with platinum and 5FU has become a
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …

5505 Background: Cetuximab in combination with platinum and 5FU (PFEx) has become a
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …